Yes / Vandetanib is an orally available tyrosine kinase inhibitor used in the treatment of cancer. The current
synthesis proceeds via an unstable 4-chloroquinazoline, using harsh reagents, in addition to requiring
sequential protection and deprotection steps. In the present work, use of the Dimroth rearrangement
in the key quinazoline forming step enabled the synthesis of Vandetanib in nine steps (compared to
the previously reported 12–14). / This work was supported by the Cancer Research UK-Cancer Imaging Centre (grant: C1060/ A16464), the Institute of Cancer Research and the University of Hull.
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/17298 |
| Date | 10 October 2019 |
| Creators | Brocklesby, K.L., Waby, Jennifer S., Cawthorne, C., Smith, G. |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, Published version |
| Rights | ©2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/)., CC-BY |
Page generated in 0.0022 seconds